pembrolizumab

targets

all catalysts(100)

News(10)

• Merck's top dealmaker signals more M&A as Keytruda's patent cliff nears
  Merck CEO Robert Davis has been landing deals “with urgency” over the last few years in an effort to shore up the pipeline ahead of Keytruda’s upcoming patent cliff. But make no mistake: The compan…
  endpoints · 1d ago
• Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
  New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will ne…
  biospace · 1d ago
• Akeso, Summit cancer drug confirms lung cancer survival benefit
  A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
  biopharma_dive · 1d ago
• Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen
  Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and GSK on the list of drugmakers to pay to access the technology this year.
  fiercebiotech · 3d ago
• Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
  BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
  biospace · 3d ago
• BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
  Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase…
  biospace · 7d ago
• BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
  Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has faltered in a reminder of the approach’s strugg…
  fiercebiotech · 7d ago
• Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say
  Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.
  biopharma_dive · 8d ago
• What’s in Merck and Moderna’s cancer vaccine algorithm?
  A heart drug failure, RevMed's pancreatic cancer drug approved, and more biotech news from The Readout
  stat · 8d ago
• Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
  The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival benefit, according to Summit Therapeutics and China-based partner Akeso.
  biospace · 9d ago